U.S. FDA inspection at Glenmark Pharma's Facility at Monroe, North Carolina, USA

The United States Food & Drug Administration (USFDA) conducted a GMP inspection at the Company's manufacturing facility situated in Monroe, North Carolina, USA from 09 June 2025 to 17 June 2025.

At the end of the inspection, the Company was issued a Form 483 with five (5) observations. All the observations are procedural in nature. There was no observation related to data integrity reported.

The Company will work in close collaboration with the agency to address the observations and will respond to the USFDA within the stipulated timeline.

Shares of Glenmark Pharmaceuticals Limited was last trading in BSE at Rs. 1653.75 as compared to the previous close of Rs. 1682.65. The total number of shares traded during the day was 12873 in over 2014 trades.

The stock hit an intraday high of Rs. 1685.20 and intraday low of 1641.35. The net turnover during the day was Rs. 21424878.00.

Source : Equity Bulls

Keywords

GlenmarkPharmaceuticals INE935A01035 USFDA Inspection Monroe NorthCarolina Form483 5Observations